Jupiter Neurosciences Inc. (JUNS)
JUNS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/0001493152-26-014687-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | JUNS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001679628 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $22K |
| Net income | -$8.6M |
| Operating income | -$8.9M |
| Net margin | -39662.8% |
| Operating margin | -40873.2% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $3.8M |
| Total assets | $5.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 102.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Our management has concluded that factors raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report;" | 10-Q 2026-08-14 |
| Cash and burn | $1.5M cash; operating cash flow -$1.8M a quarter. | Report 2026-06-30 |
| Shares outstanding | 770,081 (2026-08-14); 34,833,083 a year earlier. 1y figure adjusted for split (1-for-75 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 1; latest 1-for-75 on 2026-08-07 | Source 2026-08-07 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-24 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-28 |
| Auditor | Cherry Bekaert LLP, Tampa, Florida, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-21 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 1,318,521 shares at the 2026-11-13 price; the latest SEC cover count is 770,081 as of 2026-08-14. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $24K | -$2.3M | -$2.3M | $1.5M | $4.3M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $19K | -$2.1M | -$1.4M | $2.4M | $10.4M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$2.6M | -$2.4M | $3.8M | $11.3M | $22K | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | Not filed | -$2.3M | -$1.2M | $724K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$2.3M | -$828K | $1.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$1.5M | -$1.1M | $2.7M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$1.5M | -$3.7M | $3.8M | No debt tags | $0 | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | Not filed | -$591K | -$43K | $253 | $528K | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-09-25 |
| Latest annual report | 10-K | 2026-04-01 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-09-03 |
| Latest proxy | DEF 14A | 2026-06-22 |
Source: SEC EDGAR submissions feed, 204 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.0% |
| 1 month | -47.6% |
| 3 months | -70.7% |
| Year to date | -97.7% |
| 1 year | -98.2% |
| From 52-week high | -98.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
| ONCO | Onconetix Inc. | $2.91 | -9.35% | $1.9M |
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier